← All candidates
56 insider filings on record.
56 filings on record.
IOVAIOVANCE BIOTHERAPEUTICS, INC.
NasdaqGM · Healthcare · $4.47B
$9.87
+5.45% · Sep 16
56 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily◆ 3 8-K
▸ hover a marker for the filing · drag to zoom · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what IOVA ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$4.47B
Float
394.3M
87% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
13.8
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Commercial Officer
Kirby Daniel Gordon
Bought $55.2K on Jun 5 — 30,000 sh @ $1.84, held direct, 100% of their stake.
1 of 1 position beat the S&P
Chief Regulatory Officer
Puri Raj K.
Bought $9.7K on May 23 — 5,600 sh @ $1.74, held direct, 2.7% of their stake.
1 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
51 more transactions on Pro →The file stays open
56 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice